Martin Reck

机构：German Center for Lung Research, LungenClinic Grosshansdorf · ORCID：0000-0002-5336-9739

发表论文 636 篇 · 总被引 61038 次 · h-index 80

代表论文

• Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial (2025 · The Lancet · 被引 50)
• Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial (2025 · Journal of Clinical Oncology · 被引 45)
• Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. (2025 · Journal of Clinical Oncology · 被引 43)
• Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial (2025 · ESMO Open · 被引 24)
• Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline (2025 · Annals of Oncology · 被引 18)
• Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. (2025 · Journal of Clinical Oncology · 被引 9)